Superior Retinal Gene Transfer and Biodistribution Profile of Subretinal Versus Intravitreal Delivery of AAV8 in Nonhuman Primates
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Purpose: To investigate shedding and biodistribution characteristics of recombinant adeno-associated virus serotype 8 (rAAV8) after single-dose subretinal or intravitreal injection in nonhuman primates (NHP, Macaca fascicularis) as a surrogate for environmental hazard and patient safety. Methods: In a study for regulatory submission, 22 NHP were divided into four cohorts receiving either single subretinal injections of vehicle or clinical grade rAAV8 (1 × 1011 or 1 × 1012 vector genomes [vg]) versus single intravitreal application of 1 × 1012 vg. Viral shedding and biodistribution were monitored in biofluids for up to 91 days, followed by necropsy and tissue harvesting of all major organs, the visual pathway, and lymphatic tissue. Quantification of vector genomes was done by quantitative (q)PCR. Results: Shedding occurred in a dose-dependent manner in all biofluids and persisted for a maximum of 7 days. Intravitreal delivery led to increased and persistent (up to 13 weeks) distribution of vector genomes in blood and draining lymphatic tissue, increased off-target deposition, and inefficient gene transfer to the retina. No vector targeting of the germ line was observed in any cohort. Conclusions: These data illustrate that subretinal application of rAAV8 leads to a more favorable biodistribution profile compared to intravitreal injections. Extraocular biodistribution is limited after subretinal delivery, while intravitreal injection leads to both greater and more persistent systemic exposure, evident in blood and lymphatic tissues. With the knowledge on the dynamics of shedding in a setting mimicking clinical application, guidelines can be developed to refine clinical trial protocols to reduce the risk for trial subjects and their environment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the vitreous space, there are higher chances of exposure to systemic circulation,15 whereas the subretinal space does not expose AAV to systemic circulation, owing to the blood-retina barrier.9,33”
From Systemic and local immune responses to intraocular AAV vector administration in non-human primates (2022) · cites this paper as [15]
In the citing paper
“It has been shown that intravitreal injection results in the increased spreading of AAV particles into systemic circulation leading to adaptive responses.15”
From Systemic and local immune responses to intraocular AAV vector administration in non-human primates (2022) · cites this paper as [15]
In the citing paper
“AAV particles can be found in draining lymphoid tissues following injection in the eye (Seitz et al., 2017), where the adaptive immune response is primed.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Seitz et al., 2017
In the citing paper
“A previous study showed that IVT injection of AAV8 leads to more persistent systemic exposure than subretinal injection (Seitz et al., 2017).”
From AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery (2023) · cites this paper as Seitz et al., 2017
In the citing paper
“These higher doses may trigger a stronger immune response and increase titres of neutralising antibodies [257,258,259], which can spread through the blood and lymphatic tissues [260] and potentially lead to reduced transduction efficacy and a lack of transgene expression with repeated administration [261,262].”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [260]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273 · cited 1×
“This is evident from clinical trials, where much higher dosages of rAAV8 were delivered primarily into the systemic circulation without causing serious adverse events.(20) However, these trials have shown that systemic exposure to significant numbers of any rAAV serotype can induce humoral and cellular immune response…”
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“However, these trials have shown that systemic exposure to significant numbers of any rAAV serotype can induce humoral and cellular immune response followed by directed removal of successfully transduced target cells by cytotoxic T lymphocytes.(21) Previous studies in large animal models have demonstrated that rAAV8 g…”
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734
A Multifunctional AAV-CRISPR-Cas9 and Its Host Response
Chew, W. L., Tabebordbar, M., Cheng, J. K. W., Mali, P., Wu, E. Y., Ng, A. H. M., Zhu, K., Wagers, A. J., & Church, G. M. (2016) · Nature Methods · doi:10.1038/nmeth.3993 · Cited by 617 · cited 1×
“, CRISPR-Cas9) to edit genomic DNA with less than 100% specificity, off-target transduction may be more of a concern.(38)”
Don’t edit the human germ line
Lanphier, E., Urnov, F., Haecker, S. E., Werner, M., & Smolenski, J. (2015) · Nature · doi:10.1038/519410a · Cited by 530 · cited 1×
“One important component of patient safety is avoidance of germ line transduction.(13,14) There was no vector presence in the germ line, regardless of sex, vector dosage, or route of administration.”
Kohl, S., Marx, T., Giddings, I., Jägle, H., Jacobson, S. G., Apfelstedt-Sylla, E., Zrenner, E., Sharpe, L. T., & Wissinger, B. (1998) · Nature Genetics · doi:10.1038/935 · Cited by 340
Self-citationThe cone dysfunction syndromes: Table 1
Aboshiha, J., Dubis, A. M., Carroll, J., Hardcastle, A. J., & Michaelides, M. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-306505 · Cited by 314 · cited 1×
“Affected individuals suffer pronounced photopic defects such as total color blindness, reduced visual acuity, hemeralopia (day blindness), nystagmus, and photophobia.(3) To date, six genes have been identified that link to ACHM.”
Kohl, S. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.14.2107 · Cited by 299
Nathwani, A. C., Gray, J. T., McIntosh, J., Ng, C. Y. C., Zhou, J., Spence, Y., Cochrane, M., Gray, E., Tuddenham, E. G. D., & Davidoff, A. M. (2007) · Blood · doi:10.1182/blood-2006-03-010181 · Cited by 272
Mutations in the Cone Photoreceptor G-Protein α-Subunit Gene GNAT2 in Patients with Achromatopsia
Kohl, S., Baumann, B., Rosenberg, T., Kellner, U., Lorenz, B., Vadalà, M., Jacobson, S. G., & Wissinger, B. (2002) · The American Journal of Human Genetics · doi:10.1086/341835 · Cited by 265
Self-citation
Cited by
Cukras, C., Wiley, H. E., Jeffrey, B. G., Sen, H. N., Turriff, A., Zeng, Y., Vijayasarathy, C., Marangoni, D., Ziccardi, L., Kjellstrom, S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.025 · Cited by 268
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Self-citationClinical Perspective: Treating RPE65-Associated Retinal Dystrophy
Maguire, A. M., Bennett, J., Aleman, E. M., Leroy, B. P., & Aleman, T. S. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.029 · Cited by 184
Fischer, M. D., Michalakis, S., Wilhelm, B., Zobor, D., Muehlfriedel, R., Kohl, S., Weisschuh, N., Ochakovski, G. A., Klein, R., Schoen, C., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.1032 · Cited by 177
Self-citationYiu, G., Chung, S. H., Mollhoff, I. N., Nguyen, U. T., Thomasy, S. M., Yoo, J., Taraborelli, D., & Noronha, G. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.002 · Cited by 153
Review of gene therapies for age-related macular degeneration
Khanani, A. M., Thomas, M. J., Aziz, A. A., Weng, C. Y., Danzig, C. J., Yiu, G., Kiss, S., Waheed, N. K., & Kaiser, P. K. (2022) · Eye · doi:10.1038/s41433-021-01842-1 · Cited by 119
“In nonhuman primate studies, intravitreal AAV showed 464-fold higher outflow into systemic circulation than subretinal injections, with higher levels detected in the spleen and draining lymph nodes [66].”
BackgroundBosco, A., Anderson, S. R., Breen, K. T., Romero, C. O., Steele, M. R., Chiodo, V. A., Boye, S. L., Hauswirth, W. W., Tomlinson, S., & Vetter, M. L. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.08.017 · Cited by 110
Humoral immune response after intravitreal but not after subretinal AAV8 in primates and patients
Reichel, F. F., Peters, T., Wilhelm, B., Biel, M., Ueffing, M., Wissinger, B., Bartz-Schmidt, K. U., Klein, R., Michalakis, S., Fischer, M. D., et al. (2018) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22494 · Cited by 86
“Part of the explanation for this enhanced humoral immune response might be the fact that the shedding and biodistribution of vector after intravitreal injections is considerably higher.(21) This study has certain limitations, including absence of absolute thresholds of clinical relevance for levels of antibodies again…”
BackgroundSelf-citationDevelopment of retinal atrophy after subretinal gene therapy with voretigene neparvovec
Reichel, F. F., Seitz, I., Wozar, F., Dimopoulos, S., Jung, R., Kempf, M., Kohl, S., Kortüm, F. C., Ott, S., Pohl, L., et al. (2023) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-321023 · Cited by 79
Self-citationOcular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., et al. (2022) · Clinical Ophthalmology · doi:10.2147/opth.s364200 · Cited by 76
Reichel, F. F., Michalakis, S., Wilhelm, B., Zobor, D., Muehlfriedel, R., Kohl, S., Weisschuh, N., Sothilingam, V., Kuehlewein, L., Kahle, N., et al. (2022) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2021-319067 · Cited by 72
Self-citationRetinal Cyclic Nucleotide-Gated Channels: From Pathophysiology to Therapy
Michalakis, S., Bećirović, E., & Biel, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030749 · Cited by 75
Self-citationBritten‐Jones, A. C., Jin, R., Gocuk, S. A., Cichello, E., O’Hare, F., Hickey, D. G., Edwards, T. L., & Ayton, L. N. (2021) · Genetics in Medicine · doi:10.1016/j.gim.2021.10.013 · Cited by 67
Achromatopsia: Genetics and Gene Therapy
Michalakis, S., Gerhardt, M. J., Rudolph, G., Priglinger, S. G., & Priglinger, C. (2021) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-021-00565-z · Cited by 78
Self-citationSystemic and local immune responses to intraocular AAV vector administration in non-human primates
Ail, D., Ren, D., Brazhnikova, E., Nouvel-Jaillard, C., Bertin, S., Mirashrafi, S. B., Fisson, S., & Dalkara, D. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.011 · Cited by 61
“It has been shown that intravitreal injection results in the increased spreading of AAV particles into systemic circulation leading to adaptive responses.(15) We tested the difference in BAB and NAB levels in animals that received AAV by different modes of intraocular injection.”
BackgroundCiulla, T. A., Hussain, R. M., Berrocal, A. M., & Nagiel, A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1740676 · Cited by 59
AAV for Gene Therapy in Ocular Diseases: Progress and Prospects
He, X., Fu, Y., Ma, L., Yao, Y., Ge, S., Yang, Z. H., & Fan, X. (2023) · Research · doi:10.34133/research.0291 · Cited by 79
“4) [98].”
Host immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyes
Chung, S. H., Mollhoff, I. N., Mishra, A., Sin, T.-N., Ngo, T., Ciulla, T., Sieving, P., Thomasy, S. M., & Yiu, G. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.281 · Cited by 57
“Our biodistribution assays demonstrated greater peripheral distribution of viral genomes to the spleen and liver after intravitreal injections, compared with suprachoroidal AAV8 delivery, similar to findings by Seitz and colleagues who also found more viral genomes in peripheral organs after intravitreal versus subret…”
BackgroundGene therapy in inherited retinal degenerative diseases, a review
Takahashi, V. K. L., Takiuti, J. T., Jauregui, R., & Tsang, S. H. (2018) · Ophthalmic Genetics · doi:10.1080/13816810.2018.1495745 · Cited by 57
“showed that gene transduction was two orders of magnitude lower with intravitreal of rAAV8 compared to subretinal injection in non-human primates(10).”
ResultChan, Y. K., Dick, A. D., Hall, S. M., Langmann, T., Scribner, C. L., Mansfield, B. C., & for the Ocular Gene Therapy Inflammation Working Group (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.4.3 · Cited by 56
Chandler, L., Yusuf, I., McClements, M., Barnard, A., MacLaren, R., & Xue, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144972 · Cited by 49
“This may be because of increased vector shedding in intravitreal AAV delivery [124], while the blood-retina barrier may limit exposure to circulating antibodies and immune cells during subretinal injections.”
BackgroundHammadi, S., Tzoumas, N., Ferrara, M., Meschede, I. P., Lo, K., Harris, C., Lako, M., & Steel, D. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082870 · Cited by 44
“Subretinal gene delivery has been shown to be more effective and have a faster onset than intravitreal delivery in animal models [260,285,286].”
BackgroundTranslating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 47
“Altogether, studies show that IVT administration increases AAV exposure to the immune system.(150) Another consideration is the administration complexity and ensuing complications.”
Advances in ophthalmic optogenetics: approaches and applications
Prosseda, P. P., Tran, M., Kowal, T., Wang, B., & Sun, Y. (2022) · Biomolecules · doi:10.3390/biom12020269 · Cited by 41
“An advantage of subretinal injection is a more favorable biodistribution profile compared to intravitreal injection, thereby decreasing the risk of systemic exposure and inflammation [94].”
BackgroundBallon, D., Rosenberg, J. B., Fung, E. K., Nikolopoulou, A., Kothari, P. J., De, B. P., He, B., Chen, A., Heier, L., Sondhi, D., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.116 · Cited by 42
Immune function in X-linked retinoschisis subjects in an AAV8-RS1 phase I/IIa gene therapy trial
Mishra, A., Vijayasarathy, C., Cukras, C. A., Wiley, H. E., Sen, H. N., Zeng, Y., Wei, L. L., & Sieving, P. A. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.013 · Cited by 38
Recombinant adeno-associated virus 8 vector in gene therapy: Opportunities and challenges
Zhao, L., Yang, Z., Zheng, M., Shi, L., Gu, M., Liu, G., Miao, F., Chang, Y., Fanghua, H., & Tang, N. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.010 · Cited by 43
Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations
Talib, M., & Boon, C. J. F. (2020) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000290 · Cited by 41
Chung, S. H., Mollhoff, I. N., Nguyen, U., Nguyen, A., Stucka, N., Tieu, E., Manna, S., Meleppat, R. K., Zhang, P., Nguyen, E. L., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.006 · Cited by 34
Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33
The Blunt End: Surgical Challenges of Gene Therapy for Inherited Retinal Diseases
Davis, J. L. (2018) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2018.08.038 · Cited by 30
La thérapie génique des rétinites pigmentaires héréditaires
Ducloyer, J., Meur, G. L., Cronin, T., Adjali, O., & Weber, M. (2020) · médecine/sciences · doi:10.1051/medsci/2020095 · Cited by 44
Safety of same-eye subretinal sequential readministration of AAV2-hRPE65v2 in non-human primates
Weed, L., Ammar, M. J., Zhou, S., Wei, Z., Serrano, L. W., Sun, J., Lee, V., Maguire, A. M., Bennett, J., & Aleman, T. S. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.011 · Cited by 27
Hutt, J. A., Assaf, B. T., Bolon, B. N., Cavagnaro, J. A., Galbreath, E. J., Grubor, B., Kattenhorn, L. M., Romeike, A., & Whiteley, L. O. (2021) · Toxicologic Pathology · doi:10.1177/01926233211041962 · Cited by 28
Ferla, R., Dell’Aquila, F., Doria, M., Ferraiuolo, M. A., Noto, A., Grazioli, F., Ammendola, V., Testa, F., Melillo, P., Iodice, C., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.02.002 · Cited by 31
“Vector shedding in tears and serumwas transient and similar in duration to what was previously reported in NHPs receiving similar doses of AAV8.(22) Similarly, no AAV8 vector shedding in tears was demonstrated in subjects enrolled in a recent gene therapy clinical trial (ClinicalTrials.”
ResultOcular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions
Banou, L., Sarrafpour, S., Teng, C. C., & Liu, J. (2024) · The Yale Journal of Biology and Medicine · doi:10.59249/hwid7537 · Cited by 29
Purdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“AAV particles can be found in draining lymphoid tissues following injection in the eye (Seitz et al., 2017), where the adaptive immune response is primed.”
Self-citationKu, C. A., Wei, L. W., & Sieving, P. A. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041288 · Cited by 27
Tobias, P., Philipp, S. I., Stylianos, M., Martin, B., Barbara, W., Felix, R., Alexander, O. G., Eberhart, Z., Marius, U., Birgit, K., et al. (2019) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2018.188 · Cited by 23
Self-citationAn optimized treatment protocol for subretinal injections limits intravitreal vector distribution
Reichel, F. F. L., Wozar, F., Seitz, I., Ochakovski, A., Bartz-Schmidt, K. U., Peters, T., & Fischer, M. D. (2021) · Ophthalmology Science · doi:10.1016/j.xops.2021.100050 · Cited by 22
“A reason for this could be the enhanced and prolonged biodistribution of the vector after intravitreal injection.(11) Consequently, inadvertent placement of the vector into the vitreous (e.”
BackgroundSelf-citationChen, K.-S., Chan, H.-C., & Chan, C.-M. (2025) · Drugs · doi:10.1007/s40265-025-02237-2 · Cited by 27
“However, subretinal delivery still demonstrates superior retinal gene transfer and a more favorable biodistribution profile compared with intra-vitreal injection in nonhuman primates [87].”
Koponen, S., Kokki, E., Tamminen, T., & Ylä-Herttuala, S. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1148795 · Cited by 21
Malvasi, M., Casillo, L., Avogaro, F., Abbouda, A., & Vingolo, E. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813756 · Cited by 25
Ocular gene therapy for choroideremia: clinical trials and future perspectives
Xue, K., & MacLaren, R. E. (2018) · Expert Review of Ophthalmology · doi:10.1080/17469899.2018.1475232 · Cited by 24
“thus maximizing the probability of viral transduction [43].”
BackgroundKovacs, K. D., Ciulla, T. A., & Kiss, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2121646 · Cited by 20
“Compared with subretinal delivery, intravitreal injection of AAV demonstrated a 464-fold higher outflow into systemic circulation in nonhuman primates, leading to substantially higher levels of detection in lymph nodes and the spleen [101].”
BackgroundMacDonald, I. M., Moen, C., Duncan, J. L., Tsang, S. H., Cehajic-Kapetanovic, J., & Aleman, T. S. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.3.17 · Cited by 20
Biology, Pathobiology and Gene Therapy of CNG Channel-Related Retinopathies
Gerhardt, M. J., Priglinger, S. G., Biel, M., & Michalakis, S. (2023) · Biomedicines · doi:10.3390/biomedicines11020269 · Cited by 26
Self-citationRisk mitigation of immunogenicity: a key to personalized retinal gene therapy
Varin, J., Morival, C., Maillard, N., Adjali, O., & Cronin, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312818 · Cited by 19
“This is true for the subretinal injection (SRI) as well as intravitreal (IVT) route of injection, with the latter considered a more immunogenic route [5,35].”
BackgroundAdeno-Associated Virus Vector Mobilization, Risk Versus Reality
Song, L., Samulski, R. J., & Hirsch, M. L. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.118 · Cited by 21
Mannose-coupled AAV2: A second-generation AAV vector for increased retinal gene therapy efficiency
Mével, M., Pichard, V., Bouzelha, M., Álvarez‐Dorta, D., Lalys, P.-A., Provost, N., Allais, M., Mendes, A., Landagaray, E., Ducloyer, J., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101187 · Cited by 18
Intravitreal air tamponade after AAV2 subretinal injection modifies retinal EGFP distribution
Ducloyer, J., Pichard, V., Mével, M., Galy, A. H. M., Lefevre, G. M., Brument, N., Álvarez‐Dorta, D., Deniaud, D., Mendes-Madeira, A., Libeau, L., et al. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.02.006 · Cited by 16
“It is often preferred to intravitreal injection because it allows a higher efficacy and a lower systemic exposure.(1,2) The main drawback is that the treated retinal surface is limited to the area of the retinal detachment around the injection subretinal bleb.”
BackgroundDelivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration
She, K., Su, J., Wang, Q., Liu, Y., Zhong, X., Jin, X., Zhao, Q., Xiao, J., Li, R., Deng, H., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.002 · Cited by 16
“Subretinal injection leads to superior retinal gene transfer compared with intravitreal injection in nonhuman primates.(38,39) Moreover, intravitreal injection causes increased and persistent distribution of vector genomes in blood and lymphatic tissues, raising concerns regarding the immune response and off-target tr…”
BackgroundMethodJia, R., Chen, S., Wang, L., Zhang, J., Qu, B., Qiao, J., Meng, X., Yu, S., Liu, X., Xu, B., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101377 · Cited by 17
“AAV distribution is limited by subretinal injection but can still diffuse into blood and draining lymphatic tissues following intravitreal injection (Seitz et al., 2017).”
Yang, Z., Yan, L., Zhang, W., Jia, Q., An, W., & Yao, K. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1265630 · Cited by 20
Genetic therapies and potential therapeutic applications of CRISPR activators in the eye
Ng, B., Kaukonen, M. K., McClements, M. E., Shamsnajafabadi, H., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101289 · Cited by 14
Ezra-Elia, R., Obolensky, A., Ejzenberg, A., Ross, M., Mintz, D., Banin, E., & Ofri, R. (2018) · Experimental Eye Research · doi:10.1016/j.exer.2018.08.021 · Cited by 14
Singh, L. P., Yumnamcha, T., & Devi, T. S. (2018) · PubMed · Cited by 12
Short, B. G. (2020) · Toxicologic Pathology · doi:10.1177/0192623320946712 · Cited by 12
“For gene therapy with adeno-associated viral (AAV) vectors in cynomolgus monkeys, intravitreal injections are associated with a higher risk of humoral immune responses and a less favorable biodistribution profile with more viral shedding to blood and draining lymphatic tissue, increased off-target deposition, and less…”
BackgroundAAV2-antiVEGFscFv gene therapy for retinal neovascularization
Han, N., Xu, X., Liu, Y., & Luo, G. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101145 · Cited by 10
“38 In addition, vitreous injections exhibit a stronger AAV2-neutralizing antibody response than subretinal injections, potentially reducing drug ef fi cacy.”
BackgroundKirály, P., Seitz, I. P., Elsayed, M. E. A. A., Downes, S. M., Patel, C. K., Issa, P. C., Birtel, J., Mautone, L., Dulz, S., Atiskova, Y., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1331889 · Cited by 10
Self-citationDOG) German Society of Ophthalmology (Deutsche Ophthalmologische Gesellschaft, & RG) German Retina Society e. V. (Retinologische Gesellschaft e. V. (2019) · Der Ophthalmologe · doi:10.1007/s00347-019-0906-2 · Cited by 12
Hinsch, V. G., Boye, S. L., & Boye, S. E. (2025) · Human Gene Therapy · doi:10.1089/hum.2024.252 · Cited by 12
Recent advancements in polymer science for retinal diseases: New frontiers in drug delivery systems
Wang, W. J., Wang, N., Zhao, X., Su, X., & Liu, Z. (2025) · APL Bioengineering · doi:10.1063/5.0264382 · Cited by 8
“51 However, they require an invasive, surgical approach, involving the creation of an iatrogenic retinal detachment to access the subretinal space.”
Tissue Engineering and Ophthalmology
Utine, C. A., & Güven, S. (2024) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.galenos.2024.49779 · Cited by 8
“54 However, the treated area is limited to the detached retina around the injection subretinal bleb.”
Lidder, A. K., Choi, S. H., Modi, Y. S., Brodie, S. E., Davis, J. L., Gregori, N. Z., & Lam, B. L. (2023) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2023.101879 · Cited by 11
Shim, J., Kim, Y., Bak, J., Shin, S. H., Lee, K., Hwang, Y. H., Kong, H. Y., & Han, J. S. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101366 · Cited by 8
Hensman, J., Allali, Y. E., Almushattat, H., de Vente, C., Sánchez, C. I., & Boon, C. J. F. (2025) · Acta Ophthalmologica · doi:10.1111/aos.17495 · Cited by 7
“Subretinal delivery of gene therapy may offer more fa-vourable results, as the administration of subretinal viral vectors may be more efficient in transducing the trans-gene to the outer retina (Seitz et al., 2017).”
Marie, M., Churet, L., Gautron, A.-S., Farjo, R. A., Mizuyoshi, K., Stevenson, V. A., Khabou, H., Léveillard, T., Sahel, J., & Lorget, F. (2025) · Gene Therapy · doi:10.1038/s41434-025-00556-3 · Cited by 8
Sin, T.-N., Tng, N., Dragoli, J., Kumar, S. R., Villafuerte-Trisolini, C., Chung, S. H., Tu, L., Le, S. M., Shim, J. H., Pepple, K. L., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.027 · Cited by 9
Importance of nonhuman primates as a model system for gene therapy development in ophthalmology
Wozar, F., Seitz, I., Reichel, F., & Fischer, M. D. (2022) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1777-5033 · Cited by 6
“This enables a close approximation of potential trial procedures, such as complete vitrectomy, which significantly improves the eventual translation of therapies, whereas smaller body size simplifies breeding and maintenance [6,7, 21,22].”
BackgroundInfluentialSelf-citationOptogenetic therapy for retinal degenerative diseases: A review
Kasem, E., Watfa, M., Afif, A., Hasan, R., Mansour, M., Almhmoud, H., & Zaino, B. (2025) · European Journal of Ophthalmology · doi:10.1177/11206721251335560 · Cited by 6
“53,54 Nanoscope Therapeutics – a biotechnology company – has developed a novel opsin called melanopsin glutamate (Opto-mGluR6), which combines the intracellular domain of mGluR6 with the extracellular segments of melanopsin.”
Prospective approaches to gene therapy computational modeling – spotlight on viral gene therapy
Choules, M. P., Bonate, P. L., Heo, N., & Weddell, J. C. (2023) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09889-1 · Cited by 9
Chen, J.-H., Zhan, L.-J., Lv, C.-M., Teng, J.-B., & Cao, C. (2025) · Current Medical Science · doi:10.1007/s11596-025-00084-6 · Cited by 8
Newman, N. J., Schniederjan, M., Mendoza, P. R., Calkins, D. J., Yu‐Wai‐Man, P., Biousse, V., Carelli, V., Taiel, M., Rugiero, F., Singh, P., et al. (2022) · BMC Neurology · doi:10.1186/s12883-022-02787-y · Cited by 6
“The available evidence indicates that intravitreal injection is more likely to distribute rAAV vectors to the CNS than subretinal injection [15, 16].”
BackgroundLuo, W., Guo, L., Lu, L., Huang, N., Tao, Y., Zhang, Y., Cao, Y., Tian, S., Zhao, X., & Zhu, X. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101460 · Cited by 8
“These findings are consistent with the previous report of the subretinal injection of an AAV8 vector in NHPs. 17 Moreover, we observed that CYP4V2 DNA and mRNA were detectable in the contralateral, non-injected eyes of the rabbits, suggesting potential binocular benefits from unilateral subretinal…”
InfluentialAdvantages of human opsins in optogenetic visual restoration
Bica, M. T., & Cehajic‐Kapetanovic, J. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1725264 · Cited by 6
Tsaregorodtseva, T. S., Radyukhina, M. A., Ayupova, A. I., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., & Rizvanov, A. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114818 · Cited by 5
“These factors necessitate mandatory evaluation during pre-therapeutic screening [3,26,69,70,108].”
Immunobiology of a rationally-designed AAV2 capsid following intravitreal delivery in mice
Whitehead, M., Sage, A., Burgoyne, T., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. R. G. (2023) · Gene Therapy · doi:10.1038/s41434-023-00409-x · Cited by 4
Safety Evaluation of Ocular Drugs
Ramos, M. F., Attar, M., Seals, J. R., & Luhrs, K. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85704-8.00031-1 · Cited by 6
Tackling visual impairment: emerging avenues in ophthalmology
Lin, F., Su, Y., Zhao, C., Akter, F., Yao, S., Huang, S., Shao, X., & Yao, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1567159 · Cited by 10
Gene Therapy for Inherited Retinopathies: Update on Development Progress
Sun, S. Y., & Montezuma, S. R. (2018) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126418783934 · Cited by 6
“Changes in 6 genes have been identified as the culprits in this disease; the most common mutations found in achromatopsia are in genes CNGB3 and CNGA3, which encode cyclic nucleotide gated channels that are part of the cone phototransduction cascade.(26,54) Gene therapy for achromatopsia appeared to be promising in va…”
BackgroundAAV-based gene therapies for neovascular AMD
Kim, T. H., Kwon, C. Y., Song, J. Y., & Yoo, H. C. (2026) · Gene Therapy · doi:10.1038/s41434-026-00595-4 · Cited by 7
Mohanna, S. Z. M., Korecki, A. J., & Simpson, E. M. (2023) · Gene Therapy · doi:10.1038/s41434-023-00400-6 · Cited by 4
Seitz, I. P., Peters, T. M., Reichel, F. F., Bähr, A., Auch, H., Motlík, J., Ardan, T., Juhásová, J., Nemesh, Y., Juhás, Š., et al. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.12.41 · Cited by 5
“12 In many gene and cell therapies that are applied using SR injection, there is a need to target a specific subset of cells, such as in the macula.”
BackgroundSelf-citationA Penetrable AAV2 Capsid Variant for Efficient Intravitreal Gene Delivery to the Retina
He, X., Fu, Y., Xu, Y., Ma, L., Chai, P., Shi, H., Yao, Y., Ge, S., Jia, R., Wen, X., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.1.6 · Cited by 7
“12 Therefore, in recent years, ocular diseases, particularly retinal diseases, have been considered one of the most suitable conditions for AAV-mediated gene therapy.”
Alemán, T. S., Uyhazi, K. E., Román, A. J., Weber, M. L., O'Neil, E. C., Świder, M., Sumaroka, A., Maguire, K. H., Aleman, E. M., Santos, A. J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.06.035 · Cited by 8
“The presence of exogenous Lebercilin protein was confirmed on 84-31 cells and by western blot.”
Delivery of Genetic Information: Viral Vector and Nonviral Vector Gene Therapies
Gemayel, M. C., Byrne, L. C., Ciulla, T. A., & Sahel, J. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000360 · Cited by 5
DNA- and RNA-based Gene Therapies in Ophthalmology
Ciulla, T. A., Pennesi, M. E., Kiss, S., & Cunningham, E. T. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000359 · Cited by 4
(DOG), D. O. G., (BVA), B. D. A. D. E. V., & (RG), R. G. E. V. (2019) · Der Ophthalmologe · doi:10.1007/s00347-019-0885-3 · Cited by 4
Clinical and Ocular Inflammatory Inhibitors of Viral-Based Gene Therapy of the Retina
Ohlhausen, M. E., & Conrady, C. D. (2024) · Acta Microbiologica Hellenica · doi:10.3390/amh69030018 · Cited by 2
Dell’Aquila, F., Cunto, R. D., Marrocco, E., Prete, E. D., D’Alessio, A. M., Stefano, L. D., Notaro, S., Nusco, E., & Auricchio, A. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.019 · Cited by 2
Ocular toxicity, distribution, and shedding of intravitreal AAV-eqIL-10 in horses
Young, K., Hasegawa, T., Vridhachalam, N., Henderson, N., Salmon, J. H., McCall, T. F., Hirsch, M. L., & Gilger, B. C. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101360 · Cited by 2
“55 Despite the difference in dose, there was no significant difference in vgs detected in the cornea and retina.”
(DOG), D. O. G., (RG), R. G. E. V., & (BVA), B. D. A. D. E. V. (2019) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-0899-6601 · Cited by 1
“Empfehlungsgrad: ⇑⇑ ▪ Eine Anreicherung von Luxturna™ im Glaskörperraum und damit das Risiko einer geringeren Bioverfügbarkeit im Zielgewebe und/oder höhere systemische Biodistribution sollen vermieden werden.”
BackgroundWild type AAV, recombinant AAV, and Adenovirus super infection impact on AAV vector mobilizationPreprint
Song, L., Samulski, R. J., & Hirsch, M. L. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.13.094201 · Cited by 1
Moodle:データベース構築の実際(2)「小テスト」と「オンラインテキスト」について
表, 正. (2010) · 鹿児島国際大学情報処理センター研究年報
Assaf, B. T., Harper, C. G., & Phillips, J. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00034-8 · Cited by 2
Therapeutic strategies based on genetic interventions
Baek, R. C., Finn, P. F., & Martini, P. G. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99417-0.00013-6
Tam, L. C. S., Joel, J., Stampoulis, D., Little, A., Walton, A., Atkinson-Dell, R., Devine, M., Hill, J., Esteve-Rudd, J., & Ellis, S. (2024) · Research Square · doi:10.21203/rs.3.rs-4636180/v1
Chaudieu, G. (2025) · Revue Vétérinaire Clinique · doi:10.1016/j.anicom.2025.02.002
The Use of AAV Vector-based Gene Therapy in the Treatment of Ophthalmic Diseases. Literature Review
Batyrova, Z. A., Murtazalieva, A. S., Ramazanova, J. M., & Batchaev, A. S. ‐. (2025) · Ophthalmology in Russia · doi:10.18008/1816-5095-2025-2-244-250
Metadata
- Authors
- Seitz, I. P., Michalakis, S., Wilhelm, B., Reichel, F. F., Ochakovski, G. A., Zrenner, E., Ueffing, M., Biel, M., Wissinger, B., Bartz-Schmidt, K. U., Peters, T., Fischer, M. D., & for the RD-CURE Consortium
- Affiliations
- University of Tübingen (DE)
- Center for Integrated Protein Science Munich (DE)
- STZ eyetrial (DE)
- University Eye Hospital, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany
- University of Oxford (GB)
- Corresponding author
- Peters, Tobias
- ORCID
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2017-11-08
- Volume
- 58
- Issue
- 13
- Pages
- 5792
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2736625713
- Cited by
- 108
- References
- 38
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 15 · 2023: 15 · 2022: 9 · 2021: 12 · 2020: 15 · 2019: 5 · 2018: 10
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- intravitreal injection, viral shedding, tissue distribution, non-human primates, Macaca fascicularis, lymphoid tissue
- MeSH terms
- Dependovirus, Animals, Dose-Response Relationship, Drug, Female, Genetic Vectors, Macaca fascicularis, Male, Recombinant Proteins, Retina, Retinal Diseases, Tissue Distribution, Genetic Therapy, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.